Welsh Biotech Launches New Rapid Sepsis Test at BIO2025

North Wales biotech company J R Biomedical Limited launched their new rapid sepsis and inflammatory disease biomarker test, along with their panel of proprietary monoclonal and polyclonal antibodies, at the BIO2025 Convention in Boston, Massachusetts, this June.

The new rapid test detects a biomarker of the innate immune system called soluble Toll-like receptor 2, which is raised early on following an infectious or non-infectious insult to the immune system, allowing researchers and clinicians to study this key biomarker of inflammation.

Dr John Rees, founder and director of J R Biomedical said, "The IMIWN sTLR2 RAPID test kit was developed through collaboraration with researchers at Cardiff University. I am pleased that the project has reached a succsessful conclusion, with a UKCA certified 10 minute test for sepsis and inflammation". "My thanks also goes to the Welsh Government for the invaluable help and support we have received to exhibit and launch our products this summer at the BIO2025 convention in Boston".

Further information on the features of the sTLR2 RAPID test please visit imiwn.com